Why Novavax' CEO called last quarter 'the most significant' in corporate history
Novavax CEO Stanley Erck said he believes the last quarter was "the most significant in Novavax corporate history."
The reason? Vaccines, specifically clinical results from the Gaithersburg company's two lead vaccine programs: RSV for infants via maternal immunization and NanoFlu for seasonal flu.
"These are results that advance both programs in their respective clinical trials and create momentum for our exe cution during the remainder of 2018 and beyond," Erck said in a conference call with analysts…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Tina Reed Source Type: news
More News: Biotechnology | Clinical Trials | Conferences | Health Management | Nanotechnology | Vaccines